FDA Approves Roche's Enspryng, a First-in-class IL-6R Inhibitor, as First, Only At-home Subcutaneous Treatment Option for Thyroid Eye Disease
October 17, 2026
October 17, 2026
BASEL, Switzerland, Oct. 17 (TNSjou) -- Roche, a biotech company, issued the following news release:
* * *
FDA approves Roche's Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease
* FDA approval based on Phase III SatraGO-1 and -2 studies, with SatraGO-2 demonstrating a significant reduction in eye bulging (proptosis) and improvement in diplopia (double vision), with a favourab . . .
* * *
FDA approves Roche's Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease
* FDA approval based on Phase III SatraGO-1 and -2 studies, with SatraGO-2 demonstrating a significant reduction in eye bulging (proptosis) and improvement in diplopia (double vision), with a favourab . . .